Monopar Therapeutics (MNPR) Net Income towards Common Stockholders: 2017-2019
Historic Net Income towards Common Stockholders for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' Net Income towards Common Stockholders fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 31.04% down from last year.
- Latest data reveals that Monopar Therapeutics reported Net Income towards Common Stockholders of -$1.2 million as of Q4 2019, which was down 61.29% from -$759,448 recorded in Q3 2019.
- In the past 5 years, Monopar Therapeutics' Net Income towards Common Stockholders registered a high of -$373,839 during Q1 2017, and its lowest value of -$14.9 million during Q3 2017.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$828,354 (2018), whereas its average is -$2.0 million.
- Data for Monopar Therapeutics' Net Income towards Common Stockholders shows a peak YoY increase of 95.52% (in 2018) and a maximum YoY decrease of 140.01% (in 2018) over the last 5 years.
- Monopar Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$736,800 in 2017, then decreased by 25.73% to -$926,358 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
- Its Net Income towards Common Stockholders stands at -$1.2 million for Q4 2019, versus -$759,448 for Q3 2019 and -$932,109 for Q2 2019.